Galapagos: Buy The Dip
(WorldNews Health)

Shares of Belgian biotech Galapagos (GLPG) have dipped considerably in the past couple months along with general weakness in the biotech sector, potentially offering would-be investors an item point into the stock. Even after recent price action the stock has still increased by over 50% since my original recommendation in 2016 calling the firm ¨a long term buy in biotech¨. GLPG data by YCharts In my August update piece readers were reminded of several bullish drivers going forward: The company has potentially lucrative partnerships with Gilead (NASDAQ:GILD) and AbbVie (NYSE:ABBV). For the first of these involving key asset filgotinib, they received $300 million upfront in cash, a 15% equity...